Herbimycin A
(Synonyms: 除莠霉素A) 目录号 : GC15000
An inhibitor of tyrosine kinases and Hsp90
Cas No.:70563-58-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Herbimycin A is an antibiotic and a selective inhibitor of non-receptor tyrosine kinases [1].
Antibiotics are a type of antimicrobial used in the treatment of bacterial infection. Non-receptor tyrosine kinases (nRTKs) are cytoplasmic enzymes and catalyse the transfer of a phosphate group from a nucleoside triphosphate donor to tyrosine residues in proteins.
Herbimycin A is a selective non-receptor tyrosine kinases inhibitor. Herbimycin A bound to the reactive SH domains of p60v-src and p210BCR-ABL and inactivated their activity [1].
In a retinopathy prematurity rat model, Herbimycin A inhibited capillary tube formation and bovine retinal microvascular endothelial cell proliferation induced by vascular endothelial growth factor in a dose-dependent way. Also, Herbimycin A reduced pre-retinal neovascularization by 63% and 41% in oxygen-treated rats and herbimycin-injected eyes, respectively [2]. In rats exposed to heat stress, Herbimycin A exhibited thermotolerance and significantly reduced apoptosis of hepatocytes. Also, Herbimycin A inhibited caspase-3 activation [3].
References:
[1]. Fukazawa H, Uehara Y, Murakami Y, et al. Labeling of v-Src and BCR-ABL tyrosine kinases with [14C]herbimycin A and its use in the elucidation of the kinase inactivation mechanism. FEBS Lett, 1994, 340(3): 155-158.
[2]. McCollum GW, Rajaratnam VS, Bullard LE, et al. Herbimycin A inhibits angiogenic activity in endothelial cells and reduces neovascularization in a rat model of retinopathy of prematurity. Exp Eye Res, 2004, 78(5): 987-995.
[3]. Sachidhanandam SB, Lu J, Low KS, et al. Herbimycin A attenuates apoptosis during heat stress in rats. Eur J Pharmacol, 2003, 474(1): 121-128.
| Cas No. | 70563-58-5 | SDF | |
| 别名 | 除莠霉素A | ||
| 化学名 | (4Z,6E,8S,9S,10E,12S,13R,14S,16S,17R)-8,13,14,17-tetramethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | ||
| Canonical SMILES | O=C(C(NC1=O)=C2)C([C@@H]([C@@H](C)C[C@@H]([C@@H]([C@@H](C)/C=C(C)/[C@@H]([C@H](/C=C/C=C1/C)OC)OC(N)=O)OC)OC)OC)=CC2=O | ||
| 分子式 | C30H42N2O9 | 分子量 | 574.67 |
| 溶解度 | DMF: soluble,DMSO: soluble,Ethanol: soluble,Methanol: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7401 mL | 8.7006 mL | 17.4013 mL |
| 5 mM | 0.348 mL | 1.7401 mL | 3.4803 mL |
| 10 mM | 0.174 mL | 0.8701 mL | 1.7401 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet